14,727 Shares in Geron Co. (NASDAQ:GERN) Acquired by Empowered Funds LLC

Empowered Funds LLC bought a new stake in shares of Geron Co. (NASDAQ:GERN) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 14,727 shares of the biopharmaceutical company’s stock, valued at approximately $67,000.

Several other hedge funds also recently bought and sold shares of GERN. National Bank of Canada FI boosted its stake in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,000 shares during the last quarter. American Trust purchased a new stake in shares of Geron during the first quarter worth about $38,000. Rovin Capital UT ADV acquired a new position in shares of Geron in the third quarter valued at approximately $62,000. CIBC Asset Management Inc lifted its stake in shares of Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 3,805 shares during the period. Finally, Csenge Advisory Group acquired a new stake in Geron during the second quarter worth approximately $66,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Analysts Set New Price Targets

GERN has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Geron in a research note on Thursday, August 8th. HC Wainwright initiated coverage on Geron in a research note on Tuesday, November 5th. They issued a “buy” rating and a $8.00 price target on the stock. StockNews.com raised shares of Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Leerink Partners assumed coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.05.

Geron Price Performance

GERN opened at $4.06 on Wednesday. The company has a 50 day moving average of $4.20 and a two-hundred day moving average of $4.32. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.45 billion, a P/E ratio of -12.72 and a beta of 0.52.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same period in the prior year, the company earned ($0.08) EPS. The firm’s revenue was up 17138.4% on a year-over-year basis. On average, analysts expect that Geron Co. will post -0.25 earnings per share for the current year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.